Nivalis Therapeutics

About:

Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.

Website: http://www.nivalis.com/

Twitter/X: nivalisthera

Top Investors: RA Capital Management, Deerfield, Tiger Global Management, Wellington Management, Rock Springs Capital

Description:

Nivalis Therapeutics is developing a novel class of disease-modifying therapies that are designed to preserve intracellular GSNO (S-nitrosoglutathione), an endogenous molecule with cell signaling effects that are implicated in the pathophysiology of cystic fibrosis (CF).The Company’s lead candidate, N91115 initially targets patients with the F508del mutation, the most common disease-causing mutation in CF. Nivalis Therapeutics is dedicated to making a difference in the lives of patients with cystic fibrosis and their families. The company was founded in 2007 and is headquartered in Boulder, Colorado, United States.